Medscape Conference Coverage, based on selected sessions at the:

American Epilepsy Society (AES) 61st Annual Meeting

November 30 - December 04, 2007; Philadelphia, Pennsylvania

This activity is not sanctioned by, nor a part of, the American Epilepsy Society.

Conference News

  • Enzyme-Inducing AEDs Linked to Increased Vascular Risk

    Preliminary research suggests carbamazepine and phenytoin -- 2 of the most commonly used enzyme-inducing antiepileptic drugs -- may produce serologic changes that could substantially increase the risk for coronary and cerebrovascular disease.
  • Patient Survey Indicates Epilepsy Specialty Services May Be Underutilized

    Patients with active epilepsy may underutilize specialty services that could potentially offer them better seizure control and improved quality of life, a new survey suggests.
  • Noninvasive AED Drug Monitoring in Pregnancy

    A simple saliva test in pregnant and postpartum women with epilepsy may offer a less invasive, more practical and convenient method of monitoring serum concentrations of the antiepileptic drug lamotrigine.
  • Vitamin D Deficiency Highly Prevalent Among Epilepsy Patients

    New research shows almost half of all patients with epilepsy are vitamin D deficient and suggests men are equally, if not more frequently, affected.
  • Even Mild TBI Increases Epilepsy Risk in Children and Young Adults

    A large population-based study shows even mild head injury in children and young adults significantly increases epilepsy risk up to 10 years following the initial accident and possibly beyond.
  • Levetiracetam Offers Excellent Seizure Control in Brain Tumor Patients

    The antiepileptic drug levetiracetam safely and effectively reduces seizures in patients with primary and metastatic brain tumors, without the risk of adverse drug interactions that can diminish the efficacy of chemotherapy or antiseizure treatment.
  • Call to Action: Volunteers Needed to Support Returning At-Risk Veterans

    In anticipation of the need to provide timely evaluation, diagnosis, and treatment of returning veterans, the American Epilepsy Society has launched a national voluntary initiative designed to raise awareness of the signs and symptoms of posttraumatic epilepsy.
  • AES Calls for Definitive Study to Examine Antiepileptic Drug Substitution

    The American Epilepsy Society is calling for a definitive study to determine once and for all whether substitution of brand-name antiepileptic drugs with generic agents puts some patients with epilepsy at undue risk of breakthrough seizures and/or toxicity.

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Epilepsy Society. These materials and the related activity are not sanctioned by the American Epilepsy Society or the commercial supporter of the conference and do not constitute an official part of that conference.